Pfizer’s RSV vaccine shows benefit in immunosuppressed adults
Pfizer said its respiratory syncytial virus (RSV) vaccine, Abrysvo, generated a strong immune response in a late-stage study of four groups of adults aged 18 years and older with a compromised immune system.
ENTRADAS POPULARES
Putin may discuss Ukraine peace deal with Trump
noviembre 22, 2024
Spain’s vice-president Ribera blames floods on climate change
noviembre 22, 2024
Storm lashes northwestern US, killing two people
noviembre 22, 2024
Iceland volcano erupts for tenth time in three years
noviembre 22, 2024
TRANSMISIÓN EN VIVO